Developer docs
API playgroundTry for free, no card

Search company profiles

CinCor Pharma

Full company profile

uuid00006do

Namestring
CinCor Pharma
Websiteurl
cincor.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

CinCor Pharma was a Cincinnati-based clinical-stage biopharmaceutical company founded in 2018 that developed CIN-107 (later named baxdrostat and marketed as Baxfendy), a first-in-class selective aldosterone synthase inhibitor designed to lower blood pressure by blocking the enzyme that synthesizes aldosterone. The asset targeted treatment-resistant hypertension, primary aldosteronism, and chronic kidney disease, addressing an estimated 23 million US patients whose blood pressure remained uncontrolled despite two or more existing medications and representing the first new therapeutic approach in this space in roughly two decades. Phase III trials demonstrated a 15.7 mmHg systolic reduction from baseline and a 9.8 mmHg placebo-adjusted improvement (p<0.001) at the 2 mg dose.

CinCor funded development through a $50 million Series A in 2019, a $143 million Series B in October 2021 led by General Atlantic, and an upsized ~$225 million public offering in August 2022, raising roughly $368 million in total equity before being acquired by AstraZeneca in February 2023 for $1.3-1.8 billion in upfront payments to obtain baxdrostat. The drug received FDA approval in May 2026 as Baxfendy and is being commercialized through AstraZeneca's global pharmaceutical distribution network, with peak-sales projections of $5-10 billion annually.

As of the acquisition date, CinCor operates as a wholly-owned subsidiary within AstraZeneca's cardiorenal portfolio. Its leadership team included Marc de Garidel (CEO), co-founders Catherine Pearce (COO) and Jon Isaacsohn (former CEO), and Mason W. Freeman (Executive VP of Clinical Operations). The company's product was positioned to compete in the resistant hypertension segment where no novel mechanism of action had emerged for two decades.

Short descriptiontext

CinCor Pharma was a Cincinnati-based clinical-stage biopharmaceutical company that developed CIN-107 (baxdrostat), a first-in-class aldosterone synthase inhibitor for treatment-resistant hypertension, primary aldosteronism, and chronic kidney disease, before being acquired by AstraZeneca in February 2023.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
hypertension therapeutics, aldosterone synthase inhibitors, cardiorenal pharmaceuticals, biopharmaceutical development, cardiovascular drug discovery
Industry1 code
PRIMARYHLAKABAF
Preventive Cardiology & Lipidology
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Cardiovascular Pharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Development and Commercialization
TypeOne Time License
Description

CinCor Pharma was a clinical-stage biopharmaceutical company developing CIN-107 for hypertension, primary aldosteronism, and chronic kidney disease. The company pursued drug development through clinical trials with the goal of obtaining regulatory approval for commercialization. The company was acquired by AstraZeneca in 2023 for $1.8 billion, enabling commercialization of the drug through AstraZeneca's global pharmaceutical distribution network.

biopharmadive.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1CIN-107
Description

A selective aldosterone synthase inhibitor developed for treating hypertension, primary aldosteronism, and chronic kidney disease. After acquisition by AstraZeneca, the compound was renamed baxdrostat (marketed as Baxfendy).

vcaonline.com
Core offering1 text field

CinCor Pharma developed CIN-107 (baxdrostat), a first-in-class selective aldosterone synthase inhibitor as a once-daily oral tablet for treating resistant hypertension, primary aldosteronism, and chronic kidney disease. The drug inhibits the enzyme that synthesizes aldosterone, a hormone that raises blood pressure, addressing an unmet need for approximately 23 million US patients with uncontrolled hypertension despite being on two or more medications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 2mg dose reduced systolic blood pressure by 15.7 mmHg from baseline with 9.8 mmHg placebo-adjusted reduction (p<0.001) at week 12 in patients with uncontrolled or resistant hypertension
+2 more records
Product overview1 text field

CinCor Pharma was a biopharmaceutical company that developed CIN-107 (later named baxdrostat, marketed as Baxfendy), a first-in-class selective aldosterone synthase inhibitor. The company focused on developing treatments for hypertension, primary aldosteronism, and chronic kidney disease. CinCor Pharma was acquired by AstraZeneca in February 2023 for approximately $1.3-1.8 billion, after which the drug continued through clinical trials and received FDA approval in May 2026 as Baxfendy, representing the first new therapeutic approach for uncontrolled hypertension in two decades.

Product and service1 record
1Baxfendy (baxdrostat)
CategoryCardiovascular Pharmaceuticals
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CinCor Pharma

Cardiovascular Pharmaceuticalscincor.com

CinCor Pharma was a Cincinnati-based clinical-stage biopharmaceutical company that developed CIN-107 (baxdrostat), a first-in-class aldosterone synthase inhibitor for treatment-resistant hypertension, primary aldosteronism, and chronic kidney disease, before being acquired by AstraZeneca in February 2023.

What CinCor Pharma does

CinCor Pharma was a Cincinnati-based clinical-stage biopharmaceutical company founded in 2018 that developed CIN-107 (later named baxdrostat and marketed as Baxfendy), a first-in-class selective aldosterone synthase inhibitor designed to lower blood pressure by blocking the enzyme that synthesizes aldosterone. The asset targeted treatment-resistant hypertension, primary aldosteronism, and chronic kidney disease, addressing an estimated 23 million US patients whose blood pressure remained uncontrolled despite two or more existing medications and representing the first new therapeutic approach in this space in roughly two decades. Phase III trials demonstrated a 15.7 mmHg systolic reduction from baseline and a 9.8 mmHg placebo-adjusted improvement (p<0.001) at the 2 mg dose.

CinCor funded development through a $50 million Series A in 2019, a $143 million Series B in October 2021 led by General Atlantic, and an upsized ~$225 million public offering in August 2022, raising roughly $368 million in total equity before being acquired by AstraZeneca in February 2023 for $1.3-1.8 billion in upfront payments to obtain baxdrostat. The drug received FDA approval in May 2026 as Baxfendy and is being commercialized through AstraZeneca's global pharmaceutical distribution network, with peak-sales projections of $5-10 billion annually.

As of the acquisition date, CinCor operates as a wholly-owned subsidiary within AstraZeneca's cardiorenal portfolio. Its leadership team included Marc de Garidel (CEO), co-founders Catherine Pearce (COO) and Jon Isaacsohn (former CEO), and Mason W. Freeman (Executive VP of Clinical Operations). The company's product was positioned to compete in the resistant hypertension segment where no novel mechanism of action had emerged for two decades.

CinCor Pharma firmographics

Firmographics
Name
CinCor Pharma
Website
https://cincor.com
Company type
Private
Founded year
2018
Operating status
Acquired
Headcount range
1–10 employees
Short description
CinCor Pharma was a Cincinnati-based clinical-stage biopharmaceutical company that developed CIN-107 (baxdrostat), a first-in-class aldosterone synthase inhibitor for treatment-resistant hypertension, primary aldosteronism, and chronic kidney disease, before being acquired by AstraZeneca in February 2023.
Ownership category
akta.pro rank

CinCor Pharma industry classification

Industry
Product category
Cardiovascular Pharmaceuticals
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKABAF
Preventive Cardiology & Lipidology

Keywords

  • Hypertension therapeutics
  • Aldosterone synthase inhibitors
  • Cardiorenal pharmaceuticals
  • Biopharmaceutical development
  • Cardiovascular drug discovery

Where CinCor Pharma is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

CinCor Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Development and Commercialization: CinCor Pharma was a clinical-stage biopharmaceutical company developing CIN-107 for hypertension, primary aldosteronism, and chronic kidney disease. The company pursued drug development through clinical trials with the goal of obtaining regulatory approval for commercialization. The company was acquired by AstraZeneca in 2023 for $1.8 billion, enabling commercialization of the drug through AstraZeneca's global pharmaceutical distribution network.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

CinCor Pharma product offering

Product offering

Core offering

CinCor Pharma developed CIN-107 (baxdrostat), a first-in-class selective aldosterone synthase inhibitor as a once-daily oral tablet for treating resistant hypertension, primary aldosteronism, and chronic kidney disease. The drug inhibits the enzyme that synthesizes aldosterone, a hormone that raises blood pressure, addressing an unmet need for approximately 23 million US patients with uncontrolled hypertension despite being on two or more medications.

Product overview

CinCor Pharma was a biopharmaceutical company that developed CIN-107 (later named baxdrostat, marketed as Baxfendy), a first-in-class selective aldosterone synthase inhibitor. The company focused on developing treatments for hypertension, primary aldosteronism, and chronic kidney disease. CinCor Pharma was acquired by AstraZeneca in February 2023 for approximately $1.3-1.8 billion, after which the drug continued through clinical trials and received FDA approval in May 2026 as Baxfendy, representing the first new therapeutic approach for uncontrolled hypertension in two decades.

Differentiator

Problem solved

Functional benefit

Brands

  • CIN-107: A selective aldosterone synthase inhibitor developed for treating hypertension, primary aldosteronism, and chronic kidney disease. After acquisition by AstraZeneca, the compound was renamed baxdrostat (marketed as Baxfendy).

Products and services

  • Baxfendy (baxdrostat)

Quantifiable outcome

  • 2mg dose reduced systolic blood pressure by 15.7 mmHg from baseline with 9.8 mmHg placebo-adjusted reduction (p<0.001) at week 12 in patients with uncontrolled or resistant hypertension
  • +2 more outcomes

Companies that use CinCor Pharma

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles1 record

CinCor Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

CinCor Pharma partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

CinCor Pharma competitors and assessment

Company assessment

Market position

Strengths1 record

Weaknesses4 records

Competitive moat3 records

Key risks3 records

Customer concentration

CinCor Pharma social profiles

Digital presence

CinCor Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CinCor Pharma leadership team

Management profile

Number of profiles

CinCor Pharma funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CinCor Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CinCor Pharma

What does CinCor Pharma do?

CinCor Pharma developed CIN-107 (baxdrostat), a first-in-class selective aldosterone synthase inhibitor as a once-daily oral tablet for treating resistant hypertension, primary aldosteronism, and chronic kidney disease. The drug inhibits the enzyme that synthesizes aldosterone, a hormone that raises blood pressure, addressing an unmet need for approximately 23 million US patients with uncontrolled hypertension despite being on two or more medications.

Is CinCor Pharma a public or private company?

CinCor Pharma is a private company. It is classified as corporate owned and is currently acquired.

When was CinCor Pharma founded?

CinCor Pharma was founded in 2018. It employs 1 to 10 people.

Where is CinCor Pharma based?

CinCor Pharma is headquartered in Boston, United States, in the North America region.

How does CinCor Pharma make money?

One revenue line is on record: pharmaceutical Product Development and Commercialization.

Does CinCor Pharma have an API?

No public API is recorded for CinCor Pharma.

What industry is CinCor Pharma in?

CinCor Pharma's product category is Cardiovascular Pharmaceuticals. Its primary akta.pro industry code is HLAKABAF, Preventive Cardiology & Lipidology. Its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
pharmaphorumAZ gets first okay for new hypertension drug baxdrostatThe FDA approved AstraZeneca's baxdrostat (Baxfendy) for hard-to-treat hypertension, the first drug in its class. The drug targets patients with uncontrolled blood pressure despite multiple antihypertensives, and AZ expects it to become a $5 billion-a-year product. AZ has months to build a market position before rival Mineralys's lorundrostat reaches the market.MedCity NewsFDA Approves AstraZeneca Drug With New Approach to Lowering High Blood PressureThe FDA approved AstraZeneca's baxdrostat (Baxfendy) for adults with uncontrolled hypertension, a once-daily pill that inhibits aldosterone synthase. Phase 3 trials showed significant blood pressure reductions at 1 mg and 2 mg doses, with hyperkalemia as the most common adverse reaction. AstraZeneca projects peak sales of $5 billion in hypertension and up to $10 billion in other indications.MarketScreenerAstraZeneca Gets U.S. Approval for Hypertension DrugAstraZeneca received U.S. FDA approval for Baxfendy, a new hypertension drug targeting aldosterone. The company expects peak annual sales to exceed $5 billion, and the drug is one of 20 new medicines aimed at launching by 2030.openPR.comLeading Companies Fueling Innovation and Growth in the Kidney Disease MarketThe kidney disease market is forecasted to grow to $159.58 billion by 2030, representing a compound annual growth rate of 6.9%, driven by an aging population, increased home-based dialysis adoption, and greater investment in kidney disease research. AstraZeneca acquired CinCor Pharma for $1.8 billion in January 2023 to strengthen its cardiorenal portfolio with baxdrostat, a compound targeting treatment-resistant hypertension in chronic kidney disease patients. Ceribell, Inc. received FDA clearance in April 2025 for its Clarity AI algorithm designed to detect non-convulsive seizures in pediatric patients using EEG headbands.pharmaphorumAZ uses a priority review voucher for baxdrostat filingAstraZeneca has filed for FDA approval of baxdrostat, an aldosterone synthase inhibitor for treatment-resistant hypertension, using a priority review voucher to target a decision in Q2 2026. The filing is based on the BaxHTN Phase III trial, which demonstrated statistically significant blood pressure reductions of up to 9.8 mmHg placebo-adjusted at 12 weeks. AstraZeneca acquired baxdrostat through its $1.3 billion purchase of CinCor Pharma in 2023 and is positioning the drug to be the first ASI approved, ahead of rival Mineralys and its lorundrostat candidate.pharmaphorumAHA: AZ's baxdrostat impresses in resistant hypertensionAstraZeneca's phase 3 Bax24 trial of baxdrostat demonstrated a 16.6 mm Hg reduction in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension, compared to just 2.6 mm Hg for placebo at 12 weeks. The aldosterone synthase inhibitor also showed that 71% of treated patients achieved the treatment target SBP of less than 130 mmHg versus 17% in the control group. AZ expects baxdrostat, acquired for $1.3 billion through the 2023 purchase of CinCor Pharma, to become a $5 billion-a-year product and a major driver toward its $80 billion annual revenue target by 2030, positioning the company competitively against rival Mineralys in the ASI category.GlobeNewswireTreatment-Resistant Hypertension Market is Anticipated to Showcase Immense Growth by 2032, Predicts DelveInsight | Key Companies - Idorsia, Janssen Biotech, Quantum Genomics, CinCor Pharma, Ionis PharDelveInsight projects the treatment-resistant hypertension market to grow from USD 13.4 billion in 2021 to a significant CAGR by 2032 across the 7MM. The market is driven by rising prevalence and new therapies, with key companies including Idorsia, Janssen Biotech, and Quantum Genomics.PR NewswireKidney Diseases Market Set for Remarkable Growth with 7.5% CAGR, Reaching $128.15 Billion by 2027: Leading Players Pfizer, Johnson & Johnson, Roche Driving Advances in Kidney Disease TreatmentsResearchAndMarkets.com released its 'Kidney Disease Global Market Report 2023,' projecting the global kidney diseases market to grow from $92.26 billion in 2022 to $128.15 billion by 2027, driven by a 7.5% CAGR. The report identifies North America as the dominant region in 2022 with Europe expected to be the fastest-growing market, citing rising kidney disease prevalence as a key growth driver. Among highlighted developments, AstraZeneca acquired CinCor Pharma for $1.8 billion in January 2023 to strengthen its cardiorenal portfolio.